Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines
Status:
Completed
Trial end date:
2009-12-28
Target enrollment:
Participant gender:
Summary
The study objective was to investigate the safety and efficacy of incobotulinumtoxinA
(Xeomin) during repeat dose treatment of glabellar frown lines. 801 participants with
moderate to severe glabellar frown lines at maximum frown who completed participation in one
of the studies in this program, i.e. MRZ 60201-0520/1, MRZ 60201-0527/1, MRZ 60201-0724/1, or
MRZ 60201-0741/1 were eligible to participate in this repeat-dose study.
Phase:
Phase 3
Details
Lead Sponsor:
Merz Pharmaceuticals GmbH
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA